Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.48 |
| ▸ | NOS1 | P29475 | 9/20 | 0.44 |
| ▸ | NOS2 | P35228 | 9/20 | 0.44 |
| ▸ | NOS3 | P29474 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29819459 | 1.00 | PNMT (0.48) | PNMTENPP2LOXL2NOS1NOS2 | |
| SCHEMBL5041220 | 0.83 | TAAR1 (0.57) | PNMTLOXL2NOS1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8674936 | 0.78 | ENPP2 (0.45) | ENPP2NOS1NOS2NOS3 | |
| SCHEMBL27306101 | 0.77 | HRH3 (0.50) | LOXL2NOS1NOS2NOS3HRH3 | |
| SCHEMBL6459970 | 0.76 | PNMT (0.42) | PNMTENPP2LOXL2NOS1NOS2 | |
| SCHEMBL15267169 | 0.75 | ACHE (0.35) | — | |
| SCHEMBL10422276 | 0.75 | LOXL2 (0.71) | PNMTENPP2LOXL2NOS1NOS2 | |
| SCHEMBL36008 | 0.75 | LOXL2 (0.71) | PNMTENPP2LOXL2NOS1NOS2 | |
| SCHEMBL6687526 | 0.74 | ENPP2 (0.49) | ENPP2 | |
| SCHEMBL4342311 | 0.74 | PNMT (0.40) | PNMTENPP2LOXL2NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329668-B2 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-12 | — | — | US | disclosed |
| US-20040204432-A1 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
| WO-2004075846-A2 | PYRAZOLOPURINE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204432-A1 | Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same | TPMT, HPRT1, TYMP | PNMT 2731/4885ENPP2 1001/4885LOXL2 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.